Loading
Life sciences · Journal article
Frontiers in Medicine · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Treatment options for triple-negative breast cancer (TNBC) remain extremely limited, and patients have a poor prognosis. Although chimeric antigen receptor (CAR)-T cell therapy has achieved breakthroughs in haematological malignancies, its application in solid tumours such as TNBC is hampered by challenges including antigenic heterogeneity, immune evasion, and off-target toxicity. By simultaneously targeting two tumour-associated antigens, dual-target CAR-T cell therapy may broaden antigen coverage and reduce the likelihood of antigen-negative tumour escape in preclinical models; however, their clinical efficacy and safety in TNBC remain unestablished. This study summarises the structural characteristics and functional differences among the three mainstream engineering strategies for dual-target CAR-T cell therapy, with a particular focus on the current evidence from preclinical studies in TNBC regarding target combinations such as B7-H3/CSPG4, MSLN/NKG2DLs and TROP2/B7-H3. At the same time, this paper highlights that dual-target CAR-T cell therapy for TNBC still faces key bottlenecks, including uncertainty in target selection, a narrow safety margin, immunosuppression within the tumour microenvironment, and a lack of clinical evidence. Future research should focus on establishing high-quality antigen expression profiles, optimising CAR structural design, and exploring combinatorial strategies with microenvironment-modulating agents to advance the translation of dual-target CAR-T cell therapy clinical translation of for TNBC.